A Post Market Surveillance on INFUSE Bone Graft

Inclusion Criteria:

• Has degenerative disc disease and is indicated for lumbar interbody spine fusionfrom L2-S1 with INFUSE™ Bone Graft via ALIF or OLIF technique

• Agrees to participate in the study and is able to understand and sign the InformedConsent

• The procedure planned for the patient complies with the labeling of the devices thatmay be used in the surgical procedure

• Has at least six months of nonoperative treatment prior to the study treatment

• Is at least 18 years old at the time of informed consent

Exclusion Criteria:

• Has a known hypersensitivity to recombinant human Bone Morphogenetic Protein-2,bovine Type I collagen, or to other components of the formulation

• Has any active malignancy or undergoes treatment for a malignancy, or operative siteis in the vicinity of a resected or extant tumor

• Is skeletally immature (<18 years of age or no radiographic evidence of epiphysealclosure)

• Is pregnant or lactating

• Has an active infection at the operative site or with an allergy to titanium,titanium alloy, or polyetheretherketone

• The use of the Infuse™ Bone Graft component implanted at locations other than thelower lumbar spine (e.g., cervical spine)

• Repeat applications of the Infuse™ Bone Graft component

• Has up to Grade 1 retrolisthesis

• Has hepatic or renal impairment

• Has metabolic bone disease

• Has autoimmune disease

• Has immunosuppressive disease or suppressed immune systems resulting from radiationtherapy, chemotherapy, steroid therapy, or other treatments

• Is illiterate or vulnerable (e.g., the participant is incapable of judgment or isunder tutelage) as per the investigator's assessment

• Concurrent participation in another clinical study that may confound study results

• Has a considerable risk for surgery

• Has a condition that could compromise study (e.g., mentally incompetent, alcohol ordrug abuse) as per the investigator's assessment